Herbal Medicine for the Treatment of Vascular Dementia: An Overview of Scientific Evidence

Dennis Chang, Jianxun Liu, Kellie Bilinski, Li Xu, Genevieve Z Steiner, Sai W Seto, Alan Bensoussan, Dennis Chang, Jianxun Liu, Kellie Bilinski, Li Xu, Genevieve Z Steiner, Sai W Seto, Alan Bensoussan

Abstract

Dementia is a leading cause of mental and physical disability. Vascular dementia (VaD) is the second most common cause of dementia after Alzheimer's disease (AD) constituting 10-15% of the dementia population. Currently there are no approved pharmaceutical options for VaD and the conventional anti-AD therapies provide only modest, short-term relief of symptoms associated with VaD. Herbal medicines have been used for the management of dementia-like symptoms for centuries and may provide viable therapies for VaD due to their multicomponent and multitarget approach. This review is designed to provide an updated overview on the current status of herbal medicine research, with an emphasis on Chinese herbal medicine, for the treatment of VaD or dementia. A case study is also provided to demonstrate the development process of a novel standardized complex herbal formulation for VaD. The article reveals some preliminary evidence to support the use of single and complex herbal preparations for VaD and dementia. Multiple issues in relation to clinical and preclinical research have been identified and future research directions are discussed.

Conflict of interest statement

The authors have received funding support from universities, government agencies, and industry in China and Australia in the development of SLT formula (as discussed in Section 5). The funding bodies include Ministry of Science and Technology of China, National Natural Science Foundation of China, Academy of Chinese Medical Sciences of China, Shineway Pharmaceutical Group, National Health and Medical Research Council of Australia, and Western Sydney University.

Figures

Figure 1
Figure 1
Pathophysiological mechanisms for vascular dementia.
Figure 2
Figure 2
Development process of SLT, a novel, standardized complex herbal formulation for VaD.

References

    1. Dementia Fact Sheet, World Health Organisation, 2016.
    1. Australian Institute of Health and Welfare 2012. Dementia in Australia. Cat. no. AGE 70. Canberra, Canada: AIHW, 2012.
    1. Australian Bureau of Statistics. 3303.0—Causes of Death, Australia. Canberra, Australia: Australian Bureau of Statistics; 2014.
    1. Kalaria R. N., Maestre G. E., Arizaga R., et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. The Lancet Neurology. 2008;7(9):812–826. doi: 10.1016/S1474-4422(08)70169-8.
    1. Nolan K. A., Lino M. M., Seligmann A. W., Blass J. P. Absence of vascular dementia in an autopsy series from a dementia clinic. Journal of the American Geriatrics Society. 1998;46(5):597–604. doi: 10.1111/j.1532-5415.1998.tb01076.x.
    1. Farlow M. R., Miller M. L., Pejovic V. Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Dementia and Geriatric Cognitive Disorders. 2008;25(5):408–422. doi: 10.1159/000122962.
    1. Liu J., Chang D. Vascular dementia. Journal of Complementary Medicine. 2006;5:14–20.
    1. Levine D. A., Langa K. M. Vascular cognitive impairment: disease mechanisms and therapeutic implications. Neurotherapeutics. 2011;8(3):361–373. doi: 10.1007/s13311-011-0047-z.
    1. Skoog I. Status of risk factors for vascular dementia. Neuroepidemiology. 1998;17(1):2–9. doi: 10.1159/000026147.
    1. Aggarwal N. T., DeCarli C. Vascular dementia: emerging trends. Seminars in Neurology. 2007;27(1):66–77. doi: 10.1055/s-2006-956757.
    1. Sachdev P., Brodaty H. Vascular dementia: an Australian perspective. Alzheimer Disease and Associated Disorders. 1999;13, supplement 3:S206–S212.
    1. Shim H. Vascular cognitive impairment and post-stroke cognitive deficits. Current Neurology and Neuroscience Reports. 2014;14(1, article 418) doi: 10.1007/s11910-013-0418-4.
    1. Smith J. V., Luo Y. Studies on molecular mechanisms of Ginkgo biloba extract. Applied Microbiology and Biotechnology. 2004;64(4):465–472. doi: 10.1007/s00253-003-1527-9.
    1. Chan P. C., Xia Q., Fu P. P. Ginkgo biloba leave extract: biological, medicinal, and toxicological effects. Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis & Ecotoxicology Reviews. 2007;25(3):211–244.
    1. Wang J., Chen W., Wang Y. A ginkgo biloba extract promotes proliferation of endogenous neural stem cells in vascular dementia rats. Neural Regeneration Research. 2013;8(18):1655–1662.
    1. Zhang L.-Y., Wang Y.-L. [Effects of EGb761 on hippocamal synaptic plasticity of vascular dementia rats] Chinese journal of applied physiology. 2008;24(1):36–40.
    1. Yao Z.-X., Han Z., Drieu K., Papadopoulos V. Ginkgo biloba extract (Egb 761) inhibits β-amyloid production by lowering free cholesterol levels. Journal of Nutritional Biochemistry. 2004;15(12):749–756. doi: 10.1016/j.jnutbio.2004.06.008.
    1. Hrehorovská M., Burda J., Domoráková I., Mechírová E. Effect of Tanakan on postischemic activity of protein synthesis machinery in the rat brain. General Physiology and Biophysics. 2004;23(4):457–465.
    1. Koh P.-O. Gingko biloba extract (EGb 761) prevents cerebral ischemia-induced p70S6 kinase and S6 phosphorylation. American Journal of Chinese Medicine. 2010;38(4):727–734. doi: 10.1142/S0192415X10008196.
    1. Saleem S., Zhuang H., Biswal S., Christen Y., Doré S. Ginkgo biloba extract neuroprotective action is dependent on heme oxygenase 1 in ischemic reperfusion brain injury. Stroke. 2008;39(12):3389–3396. doi: 10.1161/STROKEAHA.108.523480.
    1. Spinnewyn B., Blavet N., Clostre F. [Effects of ginkgo biloba extract on a cerebral ischemia model in gerbils] Presse Medicale. 1986;15(31):1511–1515.
    1. Rocher M.-N., Carré D., Spinnewyn B., et al. Long-term treatment with standardized Ginkgo biloba Extract (EGb 761) attenuates cognitive deficits and hippocampal neuron loss in a gerbil model of vascular dementia. Fitoterapia. 2011;82(7):1075–1080. doi: 10.1016/j.fitote.2011.07.001.
    1. Li W.-Z., Wu W.-Y., Huang H., Wu Y.-Y., Yin Y.-Y. Protective effect of bilobalide on learning and memory impairment in rats with vascular dementia. Molecular Medicine Reports. 2013;8(3):935–941. doi: 10.3892/mmr.2013.1573.
    1. Scholey A. B., Kennedy D. O. Acute, dose-dependent cognitive effects of Ginkgo biloba, Panax ginseng and their combination in healthy young volunteers: differential interactions with cognitive demand. Human Psychopharmacology. 2002;17(1):35–44. doi: 10.1002/hup.352.
    1. Zhang S.-J., Xue Z.-Y. Effect of Western medicine therapy assisted by Ginkgo biloba tablet on vascular cognitive impairment of none dementia. Asian Pacific Journal of Tropical Medicine. 2012;5(8):661–664. doi: 10.1016/S1995-7645(12)60135-7.
    1. Schneider L. S. Ginkgo biloba extract and preventing Alzheimer disease. JAMA. 2008;300(19):2306–2308. doi: 10.1001/jama.2008.675.
    1. Kanowski S., Herrmann W. M., Stephan K., Wierich W., Hörr R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry. 1996;29(2):47–56. doi: 10.1055/s-2007-979544.
    1. Ihl R., Tribanek M., Bachinskaya N., Gotaday Study Group Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761(R) in Alzheimer's disease and vascular dementia: results from a randomised controlled trial. Pharmacopsychiatry. 2012;45(2):41–46. doi: 10.1055/s-0031-1291217.
    1. Gauthier S., Schlaefke S. Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clinical Interventions in Aging. 2014;9:2065–2077. doi: 10.2147/cia.s72728.
    1. Tan M.-S., Yu J.-T., Tan C.-C., et al. Efficacy and adverse effects of Ginkgo Biloba for cognitive impairment and dementia: a systematic review and meta-analysis. Journal of Alzheimer's Disease. 2015;43(2):589–603. doi: 10.3233/jad-140837.
    1. Wang Y., Huang L.-Q., Tang X.-C., Zhang H.-Y. Retrospect and prospect of active principles from Chinese herbs in the treatment of dementia. Acta Pharmacologica Sinica. 2010;31(6):649–664. doi: 10.1038/aps.2010.46.
    1. Howes M.-J. R., Houghton P. J. Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacology Biochemistry and Behavior. 2003;75(3):513–527. doi: 10.1016/s0091-3057(03)00128-x.
    1. Zhang H. Y., Zheng C. Y., Yan H., et al. Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia. Chemico-Biological Interactions. 2008;175(1-3):396–402. doi: 10.1016/j.cbi.2008.04.049.
    1. Wang B.-S., Wang H., Wei Z.-H., Song Y.-Y., Zhang L., Chen H.-Z. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis. Journal of Neural Transmission. 2009;116(4):457–465. doi: 10.1007/s00702-009-0189-x.
    1. Adams S. H., Hoppel C. L., Lok K. H., et al. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid β-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. Journal of Nutrition. 2009;139(6):1073–1081. doi: 10.3945/jn.108.103754.
    1. Yang G., Wang Y., Tian J., Liu J.-P. Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. PLoS ONE. 2013;8(9) doi: 10.1371/journal.pone.0074916.e74916
    1. Hao Z., Liu M., Liu Z., Lv D. Huperzine A for vascular dementia. Cochrane Database of Systematic Reviews. 2009;(2) doi: 10.1002/14651858.CD007365.pub2.CD007365
    1. Xing S. H., Zhu C.-X., Zhang R., An L. Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis. Evidence-Based Complementary and Alternative Medicine. 2014;2014:10. doi: 10.1155/2014/363985.363985
    1. Goel A., Kunnumakkara A. B., Aggarwal B. B. Curcumin as ‘Curecumin’: from kitchen to clinic. Biochemical Pharmacology. 2008;75(4):787–809. doi: 10.1016/j.bcp.2007.08.016.
    1. Ringman J. M., Frautschy S. A., Cole G. M., Masterman D. L., Cummings J. L. A potential role of the curry spice curcumin in Alzheimer's disease. Current Alzheimer Research. 2005;2(2):131–136. doi: 10.2174/1567205053585882.
    1. Yang F., Lim G. P., Begum A. N., et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. The Journal of Biological Chemistry. 2005;280(7):5892–5901. doi: 10.1074/jbc.m404751200.
    1. Ng T.-P., Chiam P.-C., Lee T., Chua H.-C., Lim L., Kua E.-H. Curry consumption and cognitive function in the elderly. American Journal of Epidemiology. 2006;164(9):898–906. doi: 10.1093/aje/kwj267.
    1. Hatcher H., Planalp R., Cho J., Torti F. M., Torti S. V. Curcumin: from ancient medicine to current clinical trials. Cellular and Molecular Life Sciences. 2008;65(11):1631–1652. doi: 10.1007/s00018-008-7452-4.
    1. Baum L., Lam C. W. K., Cheung S. K.-K., et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease [7] Journal of Clinical Psychopharmacology. 2008;28(1):110–113. doi: 10.1097/jcp.0b013e318160862c.
    1. Ringman J. M., Cole G., Teng E., et al. Oral curcumin for the treatment of mild-to-moderate Alzheimer's disease: tolerability and clinical and biomarker efficacy results of a placebo-controlled 24-week study. Proceedings of the Abstract of International Conference on Alzheimer's Disease; 2008; Chicago, Ill, USA.
    1. Ringman J. M., Frautschy S. A., Teng E., et al. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimer's Research and Therapy. 2012;4(5, article 43) doi: 10.1186/alzrt146.
    1. Chuang C.-M., Hsieh C.-L., Lin H.-Y., Lin J.-G. Panax Notoginseng Burk attenuates impairment of learning and memory functions and increases ED1, BDNF and β-secretase immunoreactive cells in chronic stage ischemia-reperfusion injured rats. American Journal of Chinese Medicine. 2008;36(4):685–693. doi: 10.1142/S0192415X08006156.
    1. Choi R. C. Y., Zhu J. T. T., Leung K. W., et al. A flavonol glycoside, isolated from roots of panax notoginseng, reduces amyloid-β-induced neurotoxicity in cultured neurons: signaling transduction and drug development for Alzheimer's disease. Journal of Alzheimer's Disease. 2010;19(3):795–811. doi: 10.3233/jad-2010-1293.
    1. Radad K., Gille G., Liu L., Rausch W.-D. Use of ginseng in medicine with emphasis on neurodegenerative disorders. Journal of Pharmacological Sciences. 2006;100(3):175–186. doi: 10.1254/jphs.CRJ05010X.
    1. Chu S., Gu J., Feng L., et al. Ginsenoside Rg5 improves cognitive dysfunction and beta-amyloid deposition in STZ-induced memory impaired rats via attenuating neuroinflammatory responses. International Immunopharmacology. 2014;19(2):317–326. doi: 10.1016/j.intimp.2014.01.018.
    1. Yang H., Zhang J., Breyer R. M., Chen C. Altered hippocampal long-term synaptic plasticity in mice deficient in the PGE2 EP2 receptor. Journal of Neurochemistry. 2009;108(1):295–304. doi: 10.1111/j.1471-4159.2008.05766.x.
    1. Liu J.-X., Cong W.-H., Xu L., Wang J.-N. Effect of combination of extracts of ginseng and ginkgo biloba on acetylcholine in amyloid beta-protein-treated rats determined by an improved HPLC. Acta Pharmacologica Sinica. 2004;25(9):1118–1123.
    1. Shi J., Zhang S., Tang M., et al. The 1239G/C polymorphism in exon 5 of BACE1 gene may be associated with sporadic Alzheimer's disease in Chinese Hans. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2004;124(1):54–57.
    1. Sun Y., Ke J., Ma N., Chen Z., Wang C., Cui X. [Effects of root rot on saponin content in Panax notoginseng] Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials. 2004;27(2):79–80.
    1. Choi K.-T. Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C A Meyer. Acta Pharmacologica Sinica. 2008;29(9):1109–1118. doi: 10.1111/j.1745-7254.2008.00869.x.
    1. Reay J. L., Kennedy D. O., Scholey A. B. Effects of Panax ginseng, consumed with and without glucose, on blood glucose levels and cognitive performance during sustained 'mentally demanding' tasks. Journal of Psychopharmacology. 2006;20(6):771–781. doi: 10.1177/0269881106061516.
    1. Kennedy D. O., Scholey A. B., Drewery L., Marsh V. R., Moore B., Ashton H. Electroencephalograph effects of single doses of Ginkgo biloba and Panax ginseng in healthy young volunteers. Pharmacology Biochemistry and Behavior. 2003;75(3):701–709. doi: 10.1016/S0091-3057(03)00120-5.
    1. Heo J.-H., Lee S.-T., Chu K., et al. An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's disease. European Journal of Neurology. 2008;15(8):865–868. doi: 10.1111/j.1468-1331.2008.02157.x.
    1. Lee S.-T., Chu K., Sim J.-Y., Heo J.-H., Kim M. Panax ginseng enhances cognitive performance in Alzheimer disease. Alzheimer Disease and Associated Disorders. 2008;22(3):222–226. doi: 10.1097/WAD.0b013e31816c92e6.
    1. Heo J.-H., Lee S.-T., Oh M. J., et al. Improvement of cognitive deficit in Alzheimer's disease patients by long term treatment with Korean red ginseng. Journal of Ginseng Research. 2011;35(4):457–461. doi: 10.5142/jgr.2011.35.4.457.
    1. Steiner G. Z., Yeung A., Liu J.-X., et al. The effect of sailuotong (SLT) on neurocognitive and cardiovascular function in healthy adults: a randomised, double-blind, placebo controlled crossover pilot trial. BMC Complementary and Alternative Medicine. 2016;16, article 15 doi: 10.1186/s12906-016-0989-0.
    1. Wesnes K. A., Ward T., McGinty A., Petrini O. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology. 2000;152(4):353–361. doi: 10.1007/s002130000533.
    1. Kennedy D. O., Scholey A. B., Wesnes K. A. Differential, dose dependent changes in cognitive performance following acute administration of a Ginkgo biloba/Panax ginseng combination to healthy young volunteers. Nutritional Neuroscience. 2001;4(5):399–412. doi: 10.1080/1028415x.2001.11747376.
    1. Tian J. Ginseng may improve memory in stroke dementia patients. Proceedings of the American Stroke Association Meeting; 2003; Augusta, Canada.
    1. Gui Q. F., Yang Y. M., Ying S. H., Zhang M. M. Xueshuantong improves cerebral blood perfusion in elderly patients with lacunar infarction. Neural Regeneration Research. 2013;8(9):792–801. doi: 10.3969/j.issn.1673-5374.2013.09.003.
    1. Russo A., Borrelli F. Bacopa monniera, a reputed nootropic plant: an overview. Phytomedicine. 2005;12(4):305–317. doi: 10.1016/j.phymed.2003.12.008.
    1. Bhattacharya S. K., Bhattacharya A., Kumar A., Ghosal S. Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus. Phytotherapy Research. 2000;14(3):174–179. doi: 10.1002/(SICI)1099-1573(200005)14:3<174::AID-PTR624>;2-O.
    1. Russo A., Izzo A. A., Borrelli F., Renis M., Vanella A. Free radical scavenging capacity and protective effect of Bacopa monniera L. on DNA damage. Phytotherapy Research. 2003;17(8):870–875. doi: 10.1002/ptr.1061.
    1. Tripathi Y. B., Chaurasia S., Tripathi E., Upadhyay A., Dubey G. P. Bacopa monniera Linn. as an antioxidant: mechanism of action. Indian Journal of Experimental Biology. 1996;34(6):523–526.
    1. Kamkaew N., Scholfield C. N., Ingkaninan K., Taepavarapruk N., Chootip K. Bacopa monnieri increases cerebral blood flow in rat independent of blood pressure. Phytotherapy Research. 2013;27(1):135–138. doi: 10.1002/ptr.4685.
    1. Kar Chowdhuri D., Parmar D., Kakkar P., Shukla R., Seth P. K., Srimal R. C. Antistress effects of bacosides of Bacopa monnieri: modulation of Hsp70 expression, superoxide dismutase and cytochrome P450 activity in rat brain. Phytotherapy Research. 2002;16(7):639–645. doi: 10.1002/ptr.1023.
    1. Kishore K., Singh M. Effect of bacosides, alcoholic extract of Bacopa monniera Linn. (brahmi), on experimental amnesia in mice. Indian Journal of Experimental Biology. 2005;43(7):640–645.
    1. Singh H. K., Dhawan B. N. Neuropsychopharmacological effects of the Ayurvedic nootropic Bacopa monniera linn (Brahmi) Indian Journal of Pharmacology. 1997;29(5):359–365.
    1. Stough C., Scholey A., Cropley V., et al. Examining the cognitive effects of a special extract of Bacopa monniera (CDRI08: Keenmind): a review of ten years of research at Swinburne University. Journal of Pharmacy and Pharmaceutical Sciences. 2013;16(2):254–258. doi: 10.18433/j35g6m.
    1. Pase M. P., Kean J., Sarris J., Neale C., Scholey A. B., Stough C. The cognitive-enhancing effects of bacopa monnieri: a systematic review of randomized, controlled human clinical trials. Journal of Alternative and Complementary Medicine. 2012;18(7):647–652. doi: 10.1089/acm.2011.0367.
    1. Stough C. K., Pase M. P., Cropley V., et al. A randomized controlled trial investigating the effect of Pycnogenol and Bacopa CDRI08 herbal medicines on cognitive, cardiovascular, and biochemical functioning in cognitively healthy elderly people: the Australian Research Council Longevity Intervention (ARCLI) study protocol (ANZCTR12611000487910) Nutrition Journal. 2012;11, article 11 doi: 10.1186/1475-2891-11-11.
    1. Amin B., Abnous K., Motamedshariaty V., Hosseinzadeh H. Attenuation of oxidative stress, inflammation and apoptosis by ethanolic and aqueous extracts of Crocus sativus L. stigma after chronic constriction injury of rats. Anais da Academia Brasileira de Ciências. 2014;86(4):1821–1832. doi: 10.1590/0001-3765201420140067.
    1. Abe K., Saito H. Effects of saffron extract and its constituent crocin on learning behaviour and long-term potentiation. Phytotherapy Research. 2000;14(3):149–152. doi: 10.1002/(SICI)1099-1573(200005)14:3<149::AID-PTR665>;2-5.
    1. Hosseinzadeh H., Ziaei T. Effects of Crocus sativus stigma extract and its constituents, crocin and safranal, on intact memory and scopolamine‐induced learning deficits in rats performing the Morris water maze task. Journal of Medicinal Plants. 2006;5(19):40–50.
    1. Hosseinzadeh H., Sadeghnia H. R. Safranal, a constituent of Crocus sativus (saffron), attenuated cerebral ischemia induced oxidative damage in rat hippocampus. Journal of Pharmacy and Pharmaceutical Sciences. 2005;8(3):394–399.
    1. Jessie S. W., Krishnakantha T. P. Inhibition of human platelet aggregation and membrane lipid peroxidation by food spice, saffron. Molecular and Cellular Biochemistry. 2005;278(1):59–63. doi: 10.1007/s11010-005-5155-9.
    1. Ancient Chinese pharmacopoeia. Il Policlinico. Sezione Pratica. 1950;57(34):1108–1109.
    1. Akhondzadeh S., Sabet M. S., Harirchian M. H., et al. A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease. Psychopharmacology. 2010;207(4):637–643. doi: 10.1007/s00213-009-1706-1.
    1. Akhondzadeh S., Sabet M. S., Harirchian M. H., et al. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. 2010;35(5):581–588. doi: 10.1111/j.1365-2710.2009.01133.x.
    1. Mandel S. A., Amit T., Kalfon L., Reznichenko L., Youdim M. B. H. Targeting multiple neurodegenerative diseases etiologies with multimodal-acting green tea catechins. Journal of Nutrition. 2008;138(8):1578S–1583S.
    1. Sharangi A. B. Medicinal and therapeutic potentialities of tea (Camellia sinensis L.)—a review. Food Research International. 2009;42(5-6):529–535. doi: 10.1016/j.foodres.2009.01.007.
    1. Kuriyama S., Hozawa A., Ohmori K., et al. Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1. American Journal of Clinical Nutrition. 2006;83(2):355–361.
    1. Schmidt A., Hammann F., Wölnerhanssen B., et al. Green tea extract enhances parieto-frontal connectivity during working memory processing. Psychopharmacology. 2014;231(19):3879–3888. doi: 10.1007/s00213-014-3526-1.
    1. Noguchi-Shinohara M., Yuki S., Dohmoto C., et al. Consumption of green tea, but not black tea or coffee, is associated with reduced risk of cognitive decline. PLoS ONE. 2014;9(5) doi: 10.1371/journal.pone.0096013.e96013
    1. Ide K., Yamada H., Takuma N., et al. Effects of green tea consumption on cognitive dysfunction in an elderly population: a randomized placebo-controlled study. Nutrition Journal. 2016;15(1, article 49) doi: 10.1186/s12937-016-0168-7.
    1. Wagner H., Ulrich-Merzenich G. Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine. 2009;16(2-3):97–110. doi: 10.1016/j.phymed.2008.12.018.
    1. Zhou X., Seto S. W., Chang D., et al. Synergistic effects of chinese herbal medicine: a comprehensive review of methodology and current research. Frontiers in Pharmacology. 2016;7, article 201 doi: 10.3389/fphar.2016.00201.
    1. Gu P., Chen H. Modern bioinformatics meets traditional Chinese medicine. Briefings in Bioinformatics. 2013;15(6):984–1003. doi: 10.1093/bib/bbt063.bbt063
    1. Iwasaki K., Kobayashi S., Chimura Y., et al. A randomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine ‘Ba Wei Di Huang Wan’ in the treatment of dementia. Journal of the American Geriatrics Society. 2004;52(9):1518–1521. doi: 10.1111/j.1532-5415.2004.52415.x.
    1. Nagata K., Yokoyama E., Yamazaki T., et al. Effects of yokukansan on behavioral and psychological symptoms of vascular dementia: an open-label trial. Phytomedicine. 2012;19(6):524–528. doi: 10.1016/j.phymed.2012.02.008.
    1. Man S. C., Chan K. W., Lu J., Durairajan S. S., Liu L., Li M. Systematic review on the efficacy and safety of herbal medicines for vascular dementia. Evidence-Based Complementary and Alternative Medicine. 2012;2012:22. doi: 10.1155/2012/426215.426215
    1. Gong D., Xu J., Fan Y. Meta-analysis of clinical trials of oral Chinese herbal prescriptions for treatment of vascular dementia based on mini mental state examination scores. European Journal of Integrative Medicine. 2015;7(2):108–117. doi: 10.1016/j.eujim.2014.11.002.
    1. Xu L., Cong W., Wei C., Liu J. Effects of Weinaokang (SLT) on dysmnesia in mice models. Pharmacology and Clinics of Chinese Materia Medica. 2007;(6):60–62.
    1. Xu L., Liu J.-X., Cong W.-H., Wei C.-E. [Effects of Weinaokang capsule on intracephalic cholinergic system and capability of scavenging free radicas in chronic cerebral hypoperfusion rats] Zhongguo Zhongyao Zazhi. 2008;33(5):531–534.
    1. Cong W. H., Liu J. X., Xu L. Effects of extracts of Ginseng and Ginkgo biloba on hippocampal acetylcholine and monoamines in PDAP-pV717I transgenic mice. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi. 2007;27(9):810–813.
    1. Zhang Y., Lin L., Ren C., et al. Pharmacokinetics and brain distribution of ginkgolides after administration of Sai-Luo-Tong. Modernization of Traditional Chinese Medicine and Materia Medica. 2014;16(7):1458–1464.
    1. Cong W.-H., Yang B., Xu L., et al. Herbal extracts combination (WNK) prevents decline in spatial learning and memory in APP/PS1 mice through improvement of hippocampal Aβ plaque formation, histopathology, and ultrastructure. Evidence-based Complementary and Alternative Medicine. 2012;2012:9. doi: 10.1155/2012/478190.478190
    1. Seto S., Jenkins A., Kiat H., Bensoussan A., Liu J., Chang D. Protective effects of a standardised herbal formulation, Sailotong, on hydrogen peroxide (H2O2) induced damage in EA.HY926 Cells. The Journal of Alternative and Complementary Medicine. 2016;22(6):p. A35.
    1. Li T., Liu H.-M., Lu Y., et al. A phase I tolerance and safety study of Sailuotong capsule. Chinese Journal of New Drugs. 2012;21(1):62–67.
    1. Steiner G. Z., Yeung A., Liu J.-X., et al. The effect of Sailuotong (SLT) on neurocognitive and cardiovascular function in healthy adults: a randomised, double-blind, placebo controlled crossover pilot trial. BMC Complementary and Alternative Medicine. 2016;16(15) doi: 10.1186/s12906-016-0989-0.
    1. Liu J., Chang D., Chan D., Liu J., Bensoussan A. A randomised placebo-controlled clinical trial of a Chinese herbal medicine for the treatment of vascular dementia. Proceedings of the 2nd International Congress for Complementary Medicine Research; 2007; Munich, Germany.
    1. Chang D., Colagiuri B., Luo R. Chinese Medicine used to Treat Dementia. CRC Press; 2013. (Advances in Natural Medicines, Nutraceuticals and Neurocognition).
    1. European Medicines Agency. Guideline on Medicinal Products for the Treatment of Alzheimer's Disease and other Dementias. London, UK: European Medicines Agency; 2008.
    1. Vellas B., Coley N., Ousset P.-J., et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. The Lancet Neurology. 2012;11(10):851–859. doi: 10.1016/s1474-4422(12)70206-5.
    1. Snitz B. E., O'Meara E. S., Carlson M. C., et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA—Journal of the American Medical Association. 2009;302(24):2663–2670. doi: 10.1001/jama.2009.1913.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera